Several systemic chemotherapies (many are listed below) have become treatment options that many patients diagnosed with Appendix Cancer, Colorectal Cancers,Gastric Cancers, Pseudomyxoma Peritonei, Peritoneal Carcinomatosis, Mucinous Adenocarcinoma, Disseminated Peritoneal Adenomucinosis or DPAM and Signet Ring Cell have utilized.
HIPEC, a chemotherapy treatment delivered directly into the peritoneal cavity, is treated as a separate topic on this website (click here for HIPEC.)
Systemic chemotherapy targets cancer cells throughout the body and is delivered throughout the bloodstream.
Is systemic chemotherapy an appropriate treatment for you?
Review our Diagnostics page for more information about KRAS mutation testing, etc.
The PMP Pals' Network "Chemo Pals Resource Program" is one of the largest, PMP Pal Resource Groups that our subscribing members participate in. Participants in "Chemo Pals" are Pseudomyxoma Peritonei and Appendix Cancer patients who exchange information regarding the particular chemotherapy (ies) utilized, including results of their treatment regimens.
To participate in our "Chemo Pals Resource Program" please click on our Subscription Membership page.
Here are a variety of informative websites and articles, for your review:
This week's new postings are in red.
Assay Testing, Cell Based Oncology Assays
Exigon Diagnostics (formerly Oncotech)
Source: Exigon
Avastin (Bevacizumab)
Avastin
Avastin Use
Avastin Restriction Removed
Avastin: Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet goals
Source: Roche, Feb 2010
Bevacizumab + Xeliri* an effective alternative to Avastin+5 FU+Leucovorin+Folfiri for metastatic Colorectal Cancer
Source: ESMO-GI, July 2009
Avastin Increases Risk of GI Perforations
Source: MedScape May 2009 ***
Is Avastin Helpful for Early Stage Colon Cancer?
Source: Medscape June 2009 ***
Avastin and Xeloda Treatment for Pseudomyxoma Peritonei and Appendix Cancer
Source: Cancer Bio Ther Austria and China, Aug 2009
Carboplatin
Carboplatin
Catumaxomab (Removab)
Source: NCI
Catumaxomab: Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
Source NIH: January 2009
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Source: NIH 2008
Cetuximab (Erbitux)
EFGR Study for Colorectal Cancer: Resistance to Cetuximab and Panitumumab
Source: Journal of Clinical Oncology March 2010
KRAS Oncogene Predictor of Response to Cetuximab
Source: Medscape July 2009
Cetuximab for Liver Mets from Colorectal Cancer
Rectal Cancer Response to Cetuximab
(April 2009)
Cetuximab, Defined
Source: National Cancer Institute, 2009
KRAS mutant status helps predict survival for Colorectal Cancer patients treated with Cetuximab, Folifiri, Folfox 6
Source: ESMO GI, June 2009
Erbitux
Erbitux Use for Colon Cancer
Erbitux Q and A
Erbitux used for Colorectal cancers only effective in Wild Type KRAS mutant tumors
Source: Medscape, May 2009
Chemotherapy, General
General Chemotherapy Descriptions
Chemotherapy, General Guide
CenterWatch Clinical Trials Notification Service
Cisplatin
Effects of Cisplatin Exposure
Source: Elsevier 2008
Cisplatin Side Effects
Source: Journal of Clinical Oncology 1986
IP Cisplation Treatment for Peritoneal Carcinomatosis of the Ovaries
Combrestatin
Combrestatin
Clinical Trials
ASCO reviews NEW chemotherapy trials for GI and Colon cancers
Source: ASCO 2009
EFGR
EFGR Study for Colorectal Cancer: Resistance to Cetuximab and Panitumumab
Source: Journal of Clinical Oncology March 2010
Biomarkers Predict Outcome of EFGR Targeted Therapy Colorectal Cancers
Source: Journal of the National Cancer Inst, 2009
EFGR: Acne related side effects
Source: MedScape, 2009 ***
EFGR definition
Source: NCI
Eloxatin (see also Oxaliplatin)
Eloxatin Approved for Colorectal Cancer
Eloxatin Information Site
Flourouracil
Flourouracil
Folfox and Folfiri
Folfox
Folfiri
Folfiri
Folfiri:metastatic gastric cancer
Source: ASCO 2009
Folfox/Folfiri in lieu of surgery for advanced stage Colorectal Cancer
Source: ASCO 2009
Folfox and Folfiri for metastatic colorectal cancer
Source: Clinical Colorectal Cancer 2005
Folfiri: Systemic Chemotherapy for the Treatment of Pseudomyxoma Peritonei, Mucinous Adenocarcinoma
KRAS mutant status helps predict survival of Colorectal Cancer pts treated w/Cetuximab, Folifiri, Folfox 6
Source: ESMO GI, June 2009
Folfox and Folfiri
Phase II Study for Peritoneal Carcinomatosis
Professor P Piso, in Regensburg, Germany provides a prospective, multicenter Phase II study evaluating multimodality treatment with pre- and postoperative systemic chemotherapy with FOLFOX/Cetuximab or FOLFIRI/ Cetuximab, complete cytoreductive surgery (CRS), and HIPEC in patients with diagnosed with Peritoneal Carcinomatosis.
For more information, contact:
Prof. Dr. P. Piso
Leitender Oberarzt
Klinik und Poliklinik für Chirurgie
der UniversitätRegensburg
Franz Josef Strauß Allee 11
D-93053 Regensburg
Tel.: 0941-944-6809
Fax: 0941-944-6860
Systemic Chemotherapy
Phase II Study Tests Effectiveness of Systemic Chemo for Pseudomyxoma Peritonei
Source: Christies Hospital, Manchester UK, Aug 2008
Pseudomyxoma Peritonei Treatment with Avastin and Xeloda
Source: Cancer Bio Ther (Austria and China) Aug 2009
Pseudomyxoma Peritonei Treatment with Adjuvant Chemotherapy
Source: World Journal of Surgical Oncology 2008
HIPEC
Herceptin use for Gastric Cancer
Source: ASCO 45th Annual Meeting Report,2009
Iressa
Iressa Clinical Trials
Iressa Studies and Trials
Irinotecan
Irinotecan with 5 FU
KRAS Mutation Testing
Listing of laboratories for KRAS mutation testing
Exigon Diagnostics (formerly Oncotech)
Source: Exigon
Leucovorin
Leucovorin
Mitomycin
Mitomycin
Oxaliplatin
Oxaliplation (see also Eloxatin)
Source: Sanofi Aventis
Oxaliplatin
Thalidomide
Potential Benefits and Risks of Thalidomide
Sulindac
Sulindac (Clinoril)
Tarceva
Tarceva or Erlotinib
Tarceva Risks and Serious Side Effects
Source: MedScape 2009 ***
Tacotere
Taxotere (Docetaxel) Use for Stomach Cancer
Xeliri*
Capetcitabine + Irinotecan
Xeloda *
Xeloda web site.
Important Info about Xeloda
New Findings About the Effectiveness of Xeloda
Join Xeloda Pals Today!
Is the cost of oral chemotherapy prohibitive?
Source: MedScape 2009***
Xelox
Xelox (Capecitabine + Oxaliplatin)
Source: Journal of Clinical Oncology, 2004
Isolated Perfusion of Chemotherapy
Regional Chemotherapy via Isolated Perfusion for Cisplatin Resistant Ovarian Cancer
Source: Professor Karl Aigner, Germany 2008
Profile of Prof Karl Aigner
Prof Karl Aigner describes regional perfusion at his clinic in Bavaria via video en espanol
Chemotherapy Resource Section
Articles of General Interest
Is Systemic Chemo the Right Option for Pseudomyxoma Peritonei?
Tips for Keeping Cool this Summer while receiving Chemo
Source: PMP Pals' Network May 2009
Is Chemotherapy the Right Choice for You?
Source: PMP Pals' Network
Should US adopt UK's limits on patient chemo costs?
Source: Medline, July 2009
Are all medical treatments worth the high cost?
Source: JNCI, May 2009
Can inhibition of angiogenesis inhibitors result in tumor invasion and metastasis?
Source: Nature Review June 2009
"Chemo Brain": Is it real?
Source: New York Times, Jane Brody, August 2009
Maintenance Chemotherapy
Source: New York Times, July 2009
Suggestions for coping w/"Chemo Brain"
Source: New York Times, Jane E Brody, August 2009
Anti Nausea Medications
Emend (Aprepitant)
Source: Merck
Colorectal Cancer Care
Dr Cathy Eng, Oncologist, MD Anderson, Houston TX
Source: MD Anderson
Coping with Special Needs
Special Needs for Side Effects of Chemotherapy
Coping with Chemo
Read how this couple balances cancer chemotherapy treatment while raising their teen
Additional Chemo Resources
Special Needs for Chemotherapy Patients
CURE Magazine FREE Online!
Source: CURE Magazine
Click here to subscribe to MedScape for free weekly and daily updates for cancer care!
Health Insurance
Health Insurance Solutions
Poison Control
American Association of Poison Control Centers Toll free number: 1.800.222.1222
FDA
FDA Toll free number: 1.FDA.1088
Diet and Nutrition
Refer to the Clinical Trials page for additional information about Chemotherapy options.
This web page has been sponsored by Chris and Sherry Piekarksi, USA
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
Copyright 2010 by PMP Pals' Network/All rights reserved
